Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

Also called NCT05478161

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 137 participants (enrolled count) (from the registry)
Sponsor
NVT GmbH (from the registry)
Registry
  • NCT NCT05478161
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany, Netherlands, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05478161. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-24 (actual); primary completion 2023-12-20 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
Acronym
EMPIRE
Condition
Transcatheter Aortic Valve Implantation
Intervention (Device)
(ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
Lead sponsor
NVT GmbH (class: industry)

Record details

Record id
cardio:ct-nct05478161
Content hash
31fd4bf8a28d299cc52b662d7b6e2df1cd3f8f06995041f873027f6e50908a8a